



## Correction to: Dapagliflozin: A Review in Type 1 Diabetes

Julia Paik<sup>1</sup> · Hannah A. Blair<sup>1</sup>

Published online: 26 November 2019  
© Springer Nature 2019

**Correction to: Drugs (2019) 79:1877–1884**  
<https://doi.org/10.1007/s40265-019-01213-x>

The article Dapagliflozin: A Review in Type 1 Diabetes, written by Julia Paik and Hannah A. Blair, was originally published Online First without Open Access. After publication in volume 49, issue 17, pages 1877–1884 AstraZeneca Pharmaceuticals, LP requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by AstraZeneca Pharmaceuticals, LP. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial

use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit original author(s) and the source, provide a link to the Creative Commons licence and indicate if changes were made.

The original article has been corrected.

**Open Access** This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

---

The original article can be found online at <https://doi.org/10.1007/s40265-019-01213-x>.

---

✉ Julia Paik  
demail@springer.com

<sup>1</sup> Springer Nature, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand